Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
Status
Conditions
Details and patient eligibility
About
Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines.
The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug.
The aim of this study is to describe the inter- and intraindividual PK variability of this drug.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- patients treated with daptomycin for BJI in Lyon Center in 2012 and 2013
Exclusion criteria
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal